Tinidazole

Summary

Tinidazole (CHEMBL1220) is an approved small-molecule antiprotozoal drug (ATC G01AF21); indicated across 10 conditions including bacterial vaginosis and trichomoniasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AF21 (+2 more)
• Indications: 10 conditions
• Clinical trials: 21
• Chemistry: 247.27 Da · C8H13N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1220
Name	Tinidazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5479
ChEBI	CHEBI:63627
ATC	G01AF21, P01AB02, J01XD02
Molecular formula	C8H13N3O4S
Molecular weight	247.27
InChIKey	HJLSLZFTEKNLFI-UHFFFAOYSA-N

SMILES: CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C

IUPAC name: 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole

ChEBI definition: 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.

Pharmacological roles (ChEBI): antiprotozoal drug, antibacterial drug, antiparasitic agent, antiamoebic agent.

Also known as: CP-12,574, CP-12574, Fasigin, Fasigyn, Haisigyn, NSC-758189, Simplotan, Symplotan, Tindamax, Tinidazol, Tinidazole, Tricolam

Patent coverage: 4,997 distinct patent families (15,777 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	5.75	Potency	1778	nM	CHEMBL_ACT_3882046
LMNA	5.7	Potency	1995	nM	CHEMBL_ACT_3644837

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial vaginosis	4	MONDO:0005316	EFO:0003932
trichomoniasis	4	MONDO:0002154	DOID:1947
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
amebiasis	4	MONDO:0005644	EFO:0007144
Helicobacter pylori infectious disease	3	MONDO:0006781	EFO:1000961
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
candidiasis	3	MONDO:0002026	MONDO:0002026
vaginitis	3	MONDO:0002234	MONDO:0002234
Plasmodium vivax malaria	2	MONDO:0005921	EFO:0007445
urethritis	2	MONDO:0005297	EFO:0003878

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	5
PHASE3	4
PHASE2	4
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00334633	PHASE4	COMPLETED	Treatment of Bacterial Vaginosis (BV) With Tinidazole
NCT02942485	PHASE4	TERMINATED	Treatment of Giardia Lamblia Infections in Children
NCT03139253	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT04122287	PHASE4	UNKNOWN	Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
NCT04132479	PHASE4	COMPLETED	The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar
NCT04264663	PHASE4	UNKNOWN	Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin
NCT00003617	PHASE3	UNKNOWN	Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach
NCT00229216	PHASE3	COMPLETED	Treatment of Bacterial Vaginosis With Oral Tinidazole
NCT00313131	PHASE3	COMPLETED	Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments
NCT04652284	PHASE3	UNKNOWN	Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
NCT07088419	PHASE2	RECRUITING	Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)
NCT00322465	PHASE2	COMPLETED	NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
NCT00324142	PHASE2	WITHDRAWN	A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
NCT00811096	PHASE2	COMPLETED	Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax
NCT01591889	PHASE1	COMPLETED	Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
NCT00510614	EARLY_PHASE1	COMPLETED	Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NCT05383521	Not specified	NOT_YET_RECRUITING	Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis
NCT00787553	Not specified	UNKNOWN	Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy
NCT01070277	Not specified	UNKNOWN	Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea
NCT03412071	Not specified	UNKNOWN	Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men
NCT05126121	Not specified	UNKNOWN	Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).